Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cabometyx

- PMLiVE

Novartis cancer chief Hoppenot leaves for top job at Incyte

He ends 10-year spell at Swiss pharma giant

- PMLiVE

FDA clears BMS/AZ’s dapagliflozin at second attempt

Diabetes drug approved as companies look to end alliance

AZ agrees cancer alliance with Immunocore

Medimmune subsidiary will work with biotech on encouraging patient's immune system to tackle tumours

- PMLiVE

AstraZeneca expands personalised drug partnership with Horizon

Companies will research drug targets for targeted cancer treatments

- PMLiVE

The oncology market in Canada

Ten per cent is not enough - simple estimates of the Canadian oncology market overlook a complex picture

- PMLiVE

AstraZeneca buys BMS out of diabetes alliance

Will spend up to $4.3bn to secure sole rights to Onglyza and Forxiga

german flag

BMS and AZ pull diabetes drug in Germany

Unable to agree price with health authorities

- PMLiVE

BMS appoints leading oncologist to board

Thomas Lynch is director of Yale Cancer Center

Roche - Basel

Roche signs $1bn-plus cancer deal with Molecular Partners

Partnership could create new type of drug conjugate similar to ADCs

- PMLiVE

Celgene signs $3.3bn cancer deal with OncoMed

Includes lead candidate demcizumab

- PMLiVE

BMS/AZ’s diabetes drug among CHMP recommendations

Xigduo one of six new drugs backed in EU

- PMLiVE

Nexavar cleared for thyroid cancer by FDA

Bayer and Onyx win expansion of oncology drug’s use in US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links